A Double-Blind, Randomized, Phase II/III Study Comparing the Use of Chemoembolization Combined With Sunitinib Against Chemoembolization Combined With a Placebo in Patients With Hepatocellular Carcinoma (SATURNE).

Trial Profile

A Double-Blind, Randomized, Phase II/III Study Comparing the Use of Chemoembolization Combined With Sunitinib Against Chemoembolization Combined With a Placebo in Patients With Hepatocellular Carcinoma (SATURNE).

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 30 Dec 2016

At a glance

  • Drugs Doxorubicin (Primary) ; Sunitinib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SATURNE
  • Most Recent Events

    • 27 May 2016 Planned primary completion date changed from 1 Jul 2013 to 1 Jul 2018.
    • 27 May 2016 Status changed from recruiting to active, no longer recruiting.
    • 28 Jul 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top